Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. - Wikidata - wikimedia - TriplyDB

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.

http://www.wikidata.org/entity/Q43884231

about

The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity Effects of GLP-1 on appetite and weight Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans.Comparison of three α-glucosidase inhibitors for glycemic control and bodyweight reduction in Japanese patients with obese type 2 diabetes.Meal-anticipatory glucagon-like peptide-1 secretion in rats.Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes.A model of GLP-1 action on insulin secretion in nondiabetic subjects.Decreased gastric motility in type II diabetic patients Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome.The Reproducibility of Tc-Pertechnetate Single Photon Emission Computed Tomography (SPECT) for Measurement of Gastric Accommodation in Healthy Humans: Evaluation of the Test Results Performed at the Same Time and Different Time of the Day.Performance characteristics of the measurement of gastric volume using single photon emission computed tomography.Association of TCF7L2 allelic variations with gastric function, satiation, and GLP-1 levels.Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy Increased nutrient sensitivity and plasma concentrations of enteral hormones during duodenal nutrient infusion in functional dyspepsia.Peripheral mechanisms in appetite regulation.SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography.Fundic accommodation assessed by SPECT scanning: comparison with the gastric barostat.Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.Effects of diet soda on gut hormones in youths with diabetes.Optimizing the Care of Patients With Type 2 Diabetes Using Incretin-Based Therapy: Focus on GLP-1 Receptor Agonists.Gastrointestinal traits: individualizing therapy for obesity with drugs and devices Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers.An emerging role of glucagon-like peptide-1 in preventing advanced-glycation-end-product-mediated damages in diabetes Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans.Central control of body weight and appetite.Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion Does caloric restriction alone explain the effects of Roux-en-Y gastric bypass on glucose metabolism? Not by a long limb.Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides Measurement of Gastrointestinal and Colonic Motor Functions in Humans and Animals Peripheral mechanisms in the control of appetite and related experimental therapies in obesity.Effect of high fat-diet and obesity on gastrointestinal motility.Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP-1R activation.Contribution of endogenous glucagon-like peptide 1 to glucose metabolism after Roux-en-Y gastric bypass.Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog Is the GLP-1 system a viable therapeutic target for weight reduction?Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus.The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.Weight loss medications in Canada - a new frontier or a repeat of past mistakes?

P2860

Q26765609-A4813346-59E9-400B-AE8D-7C1AE139D3CA Q27011627-02BCED4D-5DD2-4980-A5C9-C433AD68DC83 Q33426587-6DEAC1BA-8A36-4D1D-80F7-F059152DA79B Q33622266-0CAF77DF-714A-4B3B-960E-CA31B1F9F446 Q33634407-33FB7587-4DCA-40C4-B28E-CE1F734DDBCE Q33869732-3F730CB5-AFB2-483C-A0A7-48DF27873002 Q33916585-4A142F7C-3E2F-4AB9-B95D-795FE13F1673 Q34043578-BFD38989-B6B0-44BA-8099-34873517A47D Q34269632-4DC55E00-0D96-41F2-BDEB-846C312256A7 Q34298277-9968B8A6-F09A-4993-8E48-6C9518637341 Q35017235-3C8FEC44-8B37-47B0-93A1-7AAD70502150 Q35075403-F68DFDBD-1DDD-4D5C-8A42-59A0D998F71D Q35118214-549DFC43-05B6-4F09-A973-48BFB1369B3A Q35195049-D1B7ED19-9C40-498C-B31B-8D3756963CBE Q35204654-350E2364-4586-4605-BD6B-8FF54C843255 Q35595238-697B62AA-4AB8-4085-AF1D-FE01A6E22769 Q35596111-65CB3930-B7F5-4649-AA24-49B182AD21A6 Q35780892-FF5806D3-7837-4457-84BC-6F1F558AE463 Q35898300-7795759E-7179-4E13-B8F9-8CE1A4AB7FA5 Q35906506-1DCB86EB-ADD2-4DBE-AD5A-7563185109DA Q35994552-B8085883-2147-49D4-9C83-CF5379DA4DDA Q36248001-BCA926E8-4CA7-42AC-A6E4-0B52A68546A9 Q36535937-57280F15-90B2-4126-83A1-ACF80F941FE8 Q36567296-2E0B1A17-A964-4348-9B08-F1779E60CF08 Q36706802-2D57D3C4-8687-465F-BDF1-884BF6FD81C5 Q36882784-2454A824-E6A1-4689-8FB5-17A2FB318E93 Q36979763-F7EDC68E-B102-4550-9678-B99E8286AEBF Q37061286-5E943983-E4B1-48D2-90DF-A8AEE388F91A Q37110503-B3C5125C-00BB-4A0C-A9F2-746A6CD6817B Q37212333-5B014A72-E4FC-4698-B791-CD4723B01B72 Q37261844-B9E09144-7D69-4A78-83D0-13FB49249D9F Q37467184-F71C4411-DBEA-4CF5-A22C-70DAB3B1BEA3 Q37473305-F886B954-C637-4D40-8EF1-CB2E6EF27C82 Q37635255-D2C5C3C7-10FA-4C73-8480-EFA1E4D4581E Q37670181-07276F6A-5152-460A-B956-B2B374249D00 Q37726837-62707C50-CBDE-4C5A-8DB7-DC1392A9A9EA Q37845218-96F1B99A-0280-4007-94E9-ED515FF1D476 Q41863397-3AF6CF1F-9ED9-4D35-A2D8-266EC2464103 Q41883921-70A41599-27F2-4885-8AA4-0E18DB9E2E4D Q42373191-8F06B9F2-1A73-47D3-AD18-DDE8A8AAFDD4

P2860

Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans.

http://www.wikidata.org/entity/Q43884231

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

2002年學術文章

@zh-hant

name

Effect of GLP-1 on gastric vol ...... stprandial symptoms in humans.

@en

Effect of GLP-1 on gastric vol ...... stprandial symptoms in humans.

@nl

type

label

Effect of GLP-1 on gastric vol ...... stprandial symptoms in humans.

@en

Effect of GLP-1 on gastric vol ...... stprandial symptoms in humans.

@nl

prefLabel

Effect of GLP-1 on gastric vol ...... stprandial symptoms in humans.

@en

Effect of GLP-1 on gastric vol ...... stprandial symptoms in humans.

@nl

P1433

Q43884231-E8B5567E-10AC-4E9D-9878-CF31AB843F43

P1476

Q43884231-8CF959E0-5920-49DB-A70C-EE58B3683691

P2093

Q43884231-298850ED-05CB-4026-A3F1-6D4C7878A035

Q43884231-2CAF5A48-032D-47D7-97BC-0FDF4C5CFCFB

Q43884231-57784605-B457-4584-8AA4-2A3E8F1185DD

Q43884231-9992938B-FCE7-4AE6-97ED-DB9AF31CAC7B

Q43884231-B5A1B469-C845-4DFE-8829-4FB5BD4073B3

Q43884231-B974CE0E-3F00-4D30-A0D6-6A3E965795BD

Q43884231-E1B75DE2-1BB5-412E-8F1E-D1F0889DD3B8

P2860

Q43884231-03C32988-869D-4B1B-B142-1B9ED4F95B79

Q43884231-053463D0-8BC8-4F0F-8E7C-E7D6E8A778EA

Q43884231-100EAFB7-5189-46B0-BACC-F388DD672B7E

Q43884231-1EB6D666-EB9A-4D57-9821-0A933E5E818B

Q43884231-29BD8590-712B-469B-AE7B-ACB866A6CCCF

Q43884231-35892061-6B66-4796-998E-E1D46EA77F20

Q43884231-3889ABEF-D6A7-4956-B061-CCA7DDC30DBD

Q43884231-44B001BF-908F-4D7B-BD53-210B2A8CBE3D

Q43884231-502C5168-3EB4-4CD7-81F3-377801730F8D

Q43884231-51EEF44F-7085-4C92-9416-78BA7F2C8C35

P304

Q43884231-65AC2662-D6B4-4AF8-AAE9-422CE90906D1

P31

Q43884231-404C4A83-10D0-4E26-BF00-CBD60BCD506F

P356

Q43884231-9F54BC84-1901-4F55-B741-4F04B0A93EA0

P433

Q43884231-1C95B15C-7690-4ADB-ACED-1C18F7B7E70D

P478

Q43884231-212A8156-F39F-4AF9-8CD5-2BB154A3D4CD

P50

Q43884231-CF7EE283-4790-47D2-8660-307038DD7EFB

P577

Q43884231-D0BDDBA8-334B-49D4-BDD5-A78EA0DC46D7

P698

Q43884231-5AAC3E6A-3990-4049-B9CB-17E88BE3FDA6

P356

AJPGI.2002.282.3.G424

P1433

American Journal of Physiology - Gastrointestinal and Liver Physiology

P1476

Effect of GLP-1 on gastric vol ...... stprandial symptoms in humans.

@en

P2093

Adrian Vella

http://www.w3.org/2001/XMLSchema#string

Benjamin H Brinkmann

http://www.w3.org/2001/XMLSchema#string

Debra Stephens

http://www.w3.org/2001/XMLSchema#string

Doe-Young Kim

http://www.w3.org/2001/XMLSchema#string

Duane D Burton

http://www.w3.org/2001/XMLSchema#string

George M Thomforde

http://www.w3.org/2001/XMLSchema#string

Silvia Delgado-Aros

http://www.w3.org/2001/XMLSchema#string

P2860

A role for glucagon-like peptide-1 in the central regulation of feeding

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation.

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable.

Responses to gastric distension in functional dyspepsia.

Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans.

Glucagon-like peptide-1: a potent regulator of food intake in humans.

Glucagon-like peptide-1(7-36) amide is a new incretin/enterogastrone candidate.

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

Gastric emptying and release of incretin hormones after glucose ingestion in humans.

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.

P304

G424-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPGI.2002.282.3.G424

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P50

Michael Camilleri

P577

2002-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11841992

http://www.w3.org/2001/XMLSchema#string